Aurora Cannabis Converts 99% of $230 Million Convertible Debenture Into 69 Million Shares

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced this morning that their early conversion option on its $230 million worth of convertible debentures due in March 2020 was a resounding success. Approximately $227.0 million worth of debt has now been converted into equity at the early conversion price, which is a notable improvement from the previous update of $216.0 million.

While excellent for Aurora’s balance sheet, the early conversion option was trivial to shareholders. The Deep Dive has reported on the matter extensively, including the resulting slide in the share price following the announcement. The early conversion price was based on a five day volume weight average price, from the period of November 18, 2019 to November 22, with the resulting convert price being C$3.2837.

As a result of the early conversion, a total 69,135,117 common shares were issued.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Any current and future unpaid interest on the debt, up to but not including March 9, 2020, was paid out by Aurora in the form of cash. A total cash figure was not provided by the issuer.

A total of $2.3 million is expected to be remaining of the original $230 million convertible debenture. That debt will come due on March 9, 2020.

Aurora Cannabis last traded at $3.58 on the TSX.


Information for this briefing was found via Sedar and Aurora Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Building the $500M-a-Year Gold Mine | Victor Cantore – Amex Gold Mining

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Aurora Cannabis: Canaccord Drops Price Target to $6

On November 9th, Aurora Cannabis (TSX: ACB) reported its fiscal first quarter financial results. The...

Friday, November 12, 2021, 04:17:00 PM

Aurora clear winner in Big 5 quarterly results

Three of Canada’s Big 5 cannabis producers have now reported their quarterly earnings this year,...

Tuesday, February 19, 2019, 02:00:30 PM

Aurora Cannabis: Stifel Lowers Rating To Hold, Price Target Falls To $10.50 From $16

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) provided a business update. The firm announced that...

Wednesday, September 9, 2020, 01:47:00 PM

Is Aurora Cannabis Dumping The Green Organic Dutchman?

Aurora Cannabis (TSX: ACB) (NYSE: ACB) appears to be shopping its final holdings in The...

Tuesday, September 3, 2019, 06:29:12 PM

Aurora Cannabis Shares Drop On Fiscal Q3 2023 Financials

Aurora Cannabis (NASDAQ: ACB) announced its financial results for the third quarter of fiscal year...

Wednesday, June 14, 2023, 09:05:25 AM